<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Drug Development

Research    Breast Cancer    Drug Development    Medical Oncology

Two-Drug Combo Shows Promise as Treatment for Aggressive Form of Breast Cancer

Research led by University of Colorado Cancer Center members points to a combination of drugs as a potential treatment option for a type of aggressive breast cancer.


Author Mark Harden | Publish Date March 27, 2024
Full Story

Community    Leukemia    Clinical Research    Drug Development

Presentation to Colorado Legislature Committee Will Highlight Breakthrough Research in Leukemia Treatment

University of Colorado (CU) Cancer Center researchers have been on the leading edge of developing new therapies for leukemia. One of the most recent breakthrough therapies has been the development of venetoclax, a B-cell lymphoma-2 inhibitor, that that has shown profound results for adults with acute myeloid leukemia (AML) and has become a standard of care for patients with this disease all over the world.


Author Rachel Sauer | Publish Date February 24, 2022
Full Story

Cancer    AstraZeneca    Drug Development

CU Cancer Center leaders visit AstraZeneca to discuss speeding drug development efforts

AstraZeneca is pharmaceutical company committed to developing novel anti-cancer drugs. The University of Colorado Cancer Center is one of the fastest-growing academic cancer research centers in the United States, with hundreds of scientists and doctors working to better understand the disease. Recently, CU Cancer Center leaders visited the AstraZeneca Research and Development Campus in Gaithersburg, Maryland to discuss how a handshake between CU’s academia and AZ’s industry could help both take steps toward the ultimate goal: speeding the delivery of new drugs to cancer patients who need them.


Author Cancer Center | Publish Date April 18, 2019
Full Story

CU Cancer Center In the News

OncLive

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 08, 2024

CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.

Full Story
News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story
Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story